The first-quarter results for Bio-Rad Laboratories, Inc. ( NYSE:BIO ) were released last week, making it a good time to...
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.